

Mohamed L Sorrow

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/124565/publications.pdf>

Version: 2024-02-01

70
papers

8,570
citations

159358

30
h-index

114278

63
g-index

72
all docs

72
docs citations

72
times ranked

7106
citing authors

#	ARTICLE	IF	CITATIONS
1	Noninfectious Pulmonary Toxicity after Allogeneic Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy, 2022, 28, 310-320.	0.6	11
2	Prediction of outcomes after second-line treatment for acute graft-versus-host disease. Blood Advances, 2022, , .	2.5	1
3	Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL. Blood, 2022, 139, 3722-3731.	0.6	28
4	Survival of patients with newly diagnosed high-grade myeloid neoplasms who do not meet standard trial eligibility. Haematologica, 2021, 106, 2114-2120.	1.7	4
5	Feasibility of geriatric assessment before transplant conditioning regimen in older HCT recipients. Bone Marrow Transplantation, 2021, 56, 726-729.	1.3	1
6	Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia. Blood, 2021, 138, 387-400.	0.6	26
7	Impact of Pretransplantation Renal Dysfunction on Outcomes after Allogeneic Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy, 2021, 27, 410-422.	0.6	13
8	Are hematopoietic cell transplant recipients with Gram-negative bacteremia spending more time outpatient while on intravenous antibiotics? Addressing trends over 10 years at a single center. Immunity, Inflammation and Disease, 2021, 9, 1786-1794.	1.3	1
9	Long-term survival with mixed chimerism in patients with AML and MDS transplanted after conditioning with targeted busulfan, fludarabine, and thymoglobulin. Bone Marrow Transplantation, 2021, , .	1.3	2
10	Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells. Biology of Blood and Marrow Transplantation, 2020, 26, 26-33.	2.0	222
11	Rituximab-based allogeneic transplant for chronic lymphocytic leukemia with comparison to historical experience. Bone Marrow Transplantation, 2020, 55, 172-181.	1.3	10
12	Need for routine examination of left ventricular ejection fraction in patients with AML. Leukemia, 2020, 34, 1169-1171.	3.3	1
13	Survival, Nonrelapse Mortality, and Relapse-Related Mortality After Allogeneic Hematopoietic Cell Transplantation: Comparing 2003-2007 Versus 2013-2017 Cohorts. Annals of Internal Medicine, 2020, 172, 229.	2.0	157
14	Regimen-intensity per count-recovery and hospitalization index: A new tool to assign regimen intensity for AML. Cancer Medicine, 2020, 9, 6515-6523.	1.3	4
15	The Association between Chronic Conditions, End-of-Life Health Care Use, and Documentation of Advance Care Planning among Patients with Cancer. Journal of Palliative Medicine, 2020, 23, 1335-1341.	0.6	18
16	Pre-transplant Comorbidities: Influence on Decision-Making and Outcomes. Advances and Controversies in Hematopoietic Transplantation and Cell Therapy, 2020, , 57-85.	0.0	0
17	Non-Infectious Pulmonary Toxicity after Allogeneic Hematopoietic Cell Transplantation (HCT): A Center for International Blood and Marrow Transplant Research (CIBMTR) Study. Blood, 2020, 136, 7-8.	0.6	0
18	Moderate or severe valvular heart disease and outcomes in allogeneic stem cell transplantation. International Journal of Cardiology, 2019, 292, 166-170.	0.8	3

#	ARTICLE	IF	CITATIONS
19	Revised Acute Myeloid Leukemia Composite Model Using the 2017 European LeukemiaNet Risk Classification. <i>JAMA Oncology</i> , 2019, 5, 1062.	3.4	14
20	Cardio-Oncology and the Intersection of Cancer and Cardiotoxicity. <i>JACC: CardioOncology</i> , 2019, 1, 314-317.	1.7	3
21	Human Rhinovirus Infections in Hematopoietic Cell Transplant Recipients: Risk Score for Progression to Lower Respiratory Tract Infection. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1011-1021.	2.0	29
22	Transplant-Associated Thrombotic Microangiopathy Is a Multifactorial Disease Unresponsive to Immunosuppressant Withdrawal. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 570-576.	2.0	51
23	Prognostic Performance of the Augmented Hematopoietic Cell Transplantation-Specific Comorbidity/Age Index in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation from Alternative Graft Sources. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1045-1052.	2.0	19
24	Pre-transplant expressions of microRNAs, comorbidities, and post-transplant mortality. <i>Bone Marrow Transplantation</i> , 2019, 54, 973-979.	1.3	4
25	Hematopoietic cell transplantation comorbidity index and risk of developing invasive fungal infections after allografting. <i>Bone Marrow Transplantation</i> , 2018, 53, 1304-1310.	1.3	12
26	Transplant Conditioning with Treosulfan/Fludarabine with or without Total Body Irradiation: A Randomized Phase II Trial in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 956-963.	2.0	18
27	Hematopoietic Cell Transplantation for Myelofibrosis: the Dynamic International Prognostic Scoring System Plus Risk Predicts Post-Transplant Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 386-392.	2.0	52
28	Antibiotic Exposure Prior to Respiratory Viral Infection Is Associated with Progression to Lower Respiratory Tract Disease in Allogeneic Hematopoietic Cell Transplant Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2293-2301.	2.0	25
29	Incorporating Physical Function and Cognition Into Mortality Risk Assessment for Acute Myeloid Leukemia—Reply. <i>JAMA Oncology</i> , 2018, 4, 1014.	3.4	2
30	Comorbidities, age, and other patient-related predictors of allogeneic hematopoietic cell transplantation outcomes. <i>Expert Review of Hematology</i> , 2018, 11, 805-816.	1.0	10
31	Prognostic Value of the Hematopoietic Cell Transplantation Comorbidity Index for Patients Undergoing Reduced-Intensity Conditioning Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 654-658.	2.0	14
32	Development and Validation of a Novel Acute Myeloid Leukemia—Composite Model to Estimate Risks of Mortality. <i>JAMA Oncology</i> , 2017, 3, 1675.	3.4	125
33	Evaluation of allogeneic transplantation in first or later minimal residual disease — negative remission following adult-inspired therapy for acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2016, 57, 2109-2118.	0.6	28
34	Cord-Blood Transplantation in Patients with Minimal Residual Disease. <i>New England Journal of Medicine</i> , 2016, 375, 944-953.	13.9	352
35	Comorbidities, Alcohol Use Disorder, and Age Predict Outcomes after Autologous Hematopoietic Cell Transplantation for Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1582-1587.	2.0	20
36	Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2117-2125.	2.0	87

#	ARTICLE	IF	CITATIONS
37	Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study. <i>Lancet Haematology</i> , 2016, 3, e119-e127.	2.2	307
38	Intensive Versus Non-Intensive Induction Therapy for Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) Using Two Different Novel Prognostic Models. <i>Blood</i> , 2016, 128, 216-216.	0.6	18
39	Multi-centre validation of the prognostic value of the haematopoietic cell transplantation-specific comorbidity index among recipient of allogeneic haematopoietic cell transplantation. <i>British Journal of Haematology</i> , 2015, 170, 574-583.	1.2	45
40	Long-term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. <i>Cancer</i> , 2015, 121, 3709-3716.	2.0	27
41	Pre-transplant comorbidity burden and post-transplant chronic graft-versus-host disease. <i>British Journal of Haematology</i> , 2015, 171, 411-416.	1.2	9
42	Number of Courses of Induction Therapy Independently Predicts Outcome after Allogeneic Transplantation for Acute Myeloid Leukemia in First Morphological Remission. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 373-378.	2.0	30
43	Reevaluation of the Pretransplant Assessment of Mortality Score after Allogeneic Hematopoietic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 848-854.	2.0	40
44	Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A Center for International Blood and Marrow Transplant Research Study. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1479-1487.	2.0	173
45	Defining vulnerability in allogeneic transplants is more complicated than the two numerical digits of age. <i>Leukemia and Lymphoma</i> , 2015, 56, 2235-2236.	0.6	0
46	Design and Validation of an Augmented Hematopoietic Cell Transplantation-Comorbidity Index Comprising Pretransplant Ferritin, Albumin, and Platelet Count for Prediction of Outcomes after Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1418-1424.	2.0	62
47	Long-Term Survival and Late Effects among One-Year Survivors of Second Allogeneic Hematopoietic Cell Transplantation for Relapsed Acute Leukemia and Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 151-158.	2.0	49
48	Long-Term Outcomes of Patients with Persistent Indolent B-Cell Malignancies Undergoing Nonmyeloablative Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 281-287.	2.0	19
49	Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in older adults. <i>Hematology American Society of Hematology Education Program</i> , 2014, 2014, 21-33.	0.9	31
50	How to Combine or Not to Combine: Optimizing Risk Assessment before Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1455-1456.	2.0	11
51	Comorbidity-Age Index: A Clinical Measure of Biologic Age Before Allogeneic Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2014, 32, 3249-3256.	0.8	361
52	Second Solid Cancers after Allogeneic Hematopoietic Cell Transplantation Using Reduced-Intensity Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1777-1784.	2.0	50
53	Avascular Necrosis of Bone after Allogeneic Hematopoietic Cell Transplantation in Children and Adolescents. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 587-592.	2.0	33
54	Hematopoietic Cell Transplant Comorbidity Index Is Predictive of Survival after Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 402-408.e1.	2.0	98

#	ARTICLE	IF	CITATIONS
55	Radiolabeled Anti-CD45 Antibody with Reduced-Intensity Conditioning and Allogeneic Transplantation for Younger Patients with Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1363-1368.	2.0	54
56	Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality. <i>Blood</i> , 2014, 124, 287-295.	0.6	83
57	Allogeneic Hematopoietic Cell Transplantation following Minimal Intensity Conditioning: Predicting Acute Graft-versus-Host Disease and Graft-versus-Tumor Effects. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 792-798.	2.0	27
58	Graft-Versus-Host Disease and Graft-Versus-Tumor Effects After Allogeneic Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2013, 31, 1530-1538.	0.8	197
59	How I assess comorbidities before hematopoietic cell transplantation. <i>Blood</i> , 2013, 121, 2854-2863.	0.6	186
60	Conditioning with Treosulfan and Fludarabine followed by Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 341-350.	2.0	95
61	Long-term Outcomes Among Older Patients Following Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation for Advanced Hematologic Malignancies. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 1874.	3.8	274
62	Reduced Mortality after Allogeneic Hematopoietic-Cell Transplantation. <i>New England Journal of Medicine</i> , 2010, 363, 2091-2101.	13.9	1,335
63	Hematopoietic cell transplantation comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation. <i>Cancer</i> , 2008, 112, 1992-2001.	2.0	233
64	Five-Year Follow-Up of Patients With Advanced Chronic Lymphocytic Leukemia Treated With Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning. <i>Journal of Clinical Oncology</i> , 2008, 26, 4912-4920.	0.8	257
65	Hematopoietic cell transplantation-specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. <i>Blood</i> , 2007, 110, 4606-4613.	0.6	292
66	Comorbidity and Disease Status-Based Risk Stratification of Outcomes Among Patients With Acute Myeloid Leukemia or Myelodysplasia Receiving Allogeneic Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2007, 25, 4246-4254.	0.8	380
67	Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. <i>Blood</i> , 2005, 106, 2912-2919.	0.6	2,427
68	Graft-versus-Tumor Effects after Allogeneic Hematopoietic Cell Transplantation with Nonmyeloablative Conditioning. <i>Blood</i> , 2004, 104, 184-184.	0.6	0
69	Marrow Allografts after Nonmyeloablative Conditioning: Effect of Cell Dose on Rejection and Degree of Donor Chimerism. <i>Blood</i> , 2004, 104, 1202-1202.	0.6	0
70	Assessment of comorbidities for hematopoietic cell transplants: Achievements and controversies. , 0, 23-42.		0